DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Patent and Trademark Office has issued a new patent expanding QuantRx’s oral testing intellectual property suite. This new patent for QuantRx’s oral testing devices expands the Company’s protection, and will allow QuantRx to bring its ultrasensitive RapidSense® technology to address the exploding point-of-care market opportunity, in particular the oral DOA market.
